BIAFBioAffinity Technologies Inc
BIAF
BioAffinity Technologies Inc3,673
Mkt Cap
$6.61MVolume
58,794.0052W High
$46.5352W Low
$1.42PE Ratio
-0.07BIAF Fundamentals
Price
$1.40Prev Close
$1.47Open
$1.5150D MA
$3.33Beta
1.34Avg. Volume
2.89MEPS (Annual)
-$22.37P/B
0.57Rev/Employee
$164,246.00BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
Zacks·1d ago
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported...
Business Wire·6d ago
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath Lung, the Companys noninvasive test for lung cancer, today announced...
Business Wire·23d ago
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·1mo ago
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath Lung, the Companys commercially available test for early-stage...
Business Wire·1mo ago
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces The...
PR Newswire·1mo ago
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the...
Business Wire·1mo ago
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces...
PR Newswire·1mo ago
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered...
Business Wire·1mo ago